Inequitable conduct claims can add upwards of a million dollars to patent litigation, and adverse rulings can tank legal careers and corporate profits. The U.S. Court of Appeals for the Federal ...
Patent prosecution costs can weigh heavily on cash-strapped clients, who may still face USPTO rejections after spending significant money. Unfortunately (and often), cash-strapped clients are not ...
Luv N’ Care, Ltd. and Nouri E. Hakim v. Lindsey Laurain and Eazy-PZ, LLC, Nos. 2022-1905, 2022-1970 (Fed. Cir. April 12, 2024) addressed several issues, including: (1) what evidence of litigation ...
Inequitable conduct has long been a hot-button issue in patent litigation and, consequently, patent litigation reform. Courts and commentators have complained that litigants too often — and too ...
We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window In this video ...
At the AIPLA Annual Meeting in Washington DC last October, Michel appealed to attendees to help clarify the doctrine of inequitable conduct by bringing cases that raise the subject before the court.
We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...
Chief Judge Paul Michel of the Court of Appeals for the Federal Circuit used his speech at the AIPLA to appeal to patent practitioners to help the Court clarify the doctrine of inequitable conduct. He ...
“When a person having a duty of candor and good faith has engaged in serial misconduct during the prosecution of the same or related patents, it is not enough for a court to consider each individual ...
UTRECHT, The Netherlands, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ®), ...
In this final installment, Bob Stoll and I discuss the United States Supreme Court. We spend some time talking about the Supreme Court’s recent patent eligible subject matter decisions. We also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results